Table 1 Clinicopathologic characteristics of breast cancer.
Clinicopathologic factors | SEER (N = 36,152) | UAB (N = 4982) |
|---|---|---|
Age (median and range) | 60 (17–85+) | 58 (18–99) |
Race | ||
Caucasian | 28,341 (78.4%) | 3814 (76.6%) |
African American | 4350 (12.0%) | 1100 (22.0%) |
Other | 3208 (8.9%) | 64 (1.3%) |
Unknown | 253 (0.7%) | 4 (0.1%) |
Histologic grade | ||
I | 7009 (19.4%) | 988 (19.8%) |
II | 16,507 (45.7%) | 2228 (44.7%) |
III | 12,636 (34.9%) | 1766 (35.5%) |
Pathologic T stage | ||
T1 | 17,718 (49.0%) | 2904 (58.3%) |
T2 | 11,010 (30.5%) | 1656 (33.2%) |
T3 | 3559 (9.8%) | 391 (7.9%) |
T4 | 3865 (10.7%) | 31 (0.6%) |
Pathologic N stage | ||
N0 | 20,364 (56.3%) | 3316 (66.6%) |
N1 | 10,371 (28.7%) | 1203 (24.1%) |
N2 | 3094 (8.6%) | 307 (6.2%) |
N3 | 2323 (6.4%) | 156 (3.1%) |
M status | ||
M0 | 32,816 (90.8%) | 4886 (98.1%) |
M1 | 3336 (9.2%) | 96 (1.9%) |
ER status | ||
Positive | 30,098 (83.3%) | 3951 (79.3%) |
Negative | 6054 (16.7%) | 1031 (20.7%) |
PR status | ||
Positive | 26,302 (72.8%) | 3523 (70.1%) |
Negative | 9850 (27.2%) | 1459 (29.9%) |
HER2 status | ||
Positive | 6500 (18%) | 785 (15.8%) |
Negative | 29,652 (82%) | 4197 (84.2%) |
Clinical Prognostic Stage Group | ||
IA | 13,153 (36.4%) | 2033 (40.8%) |
IB | 5821 (16.1%) | 1015 (20.4%) |
IIA | 5420 (15.0%) | 834 (16.7%) |
IIB | 2774 (7.7%) | 482 (9.7%) |
IIIA | 1385 (3.8%) | 178 (3.6%) |
IIIB | 3231 (8.9%) | 252 (5.1%) |
IIIC | 1032 (2.9%) | 92 (1.8%) |
IV | 3336 (9.3%) | 96 (1.9%) |
